Intanza^®: a new intradermal vaccine for seasonal influenza

References

• Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Recomm. Rep.59(RR-8), 1–62 (2010).
   PubMedGoogle Scholar
• Couch RB, Kasel JA, Glezen WP et al. Influenza: its control in persons and populations. J. Infect. Dis.153(3), 431–440 (1986).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974–76. N. Engl. J. Med.298(11), 587–592 (1978).
   PubMed Web of Science ®Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine25(27), 5086–5096 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292(11), 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Lee VJ, Yap J, Ong JB et al. Influenza excess mortality from 1950–2000 in tropical Singapore. PLoS One4(12), e8096 (2009).
   PubMed Web of Science ®Google Scholar
• Simmerman JM, Chittaganpitch M, Levy J et al. Incidence, seasonality and mortality associated with influenza pneumonia in Thailand: 2005–2008. PLoS One4(11), e7776 (2009).
   PubMed Web of Science ®Google Scholar
• Callaghan WM, Chu SY, Jamieson DJ. Deaths from seasonal influenza among pregnant women in the United States, 1998–2005. Obstet. Gynecol.115(5), 919–923 (2010).
   PubMed Web of Science ®Google Scholar
• Madjid M, Miller CC, Zarubaev VV et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur. Heart J.28(10), 1205–1210 (2007).
   PubMed Web of Science ®Google Scholar
• Bhat N, Wright JG, Broder KR et al. Influenza-associated deaths among children in the United States, 2003–2004. N. Engl. J. Med.353(24), 2559–2567 (2005).
   PubMed Web of Science ®Google Scholar
• Louie JK, Schechter R, Honarmand S et al. Severe pediatric influenza in California, 2003–2005: implications for immunization recommendations. Pediatrics117(4), e610–e618 (2006).
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med.342(4), 225–231 (2000).
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Thompson WW, Kramarz P et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med.342(4), 232–239 (2000).
   PubMed Web of Science ®Google Scholar
• Chiu SS, Chan KH, Chen H et al. Virologically confirmed population-based burden of hospitalization caused by influenza A and B among children in Hong Kong. Clin. Infect. Dis.49(7), 1016–1021 (2009).
   PubMed Web of Science ®Google Scholar
• Nicoll A, Ciancio B, Tsolova S, Blank P, Yilmaz C. The scientific basis for offering seasonal influenza immunisation to risk groups in Europe. Euro Surveill.13(43), 19018 (2008).
   PubMedGoogle Scholar
• Nokleby H, Nicoll A. Risk groups and other target groups – preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010–11. Euro Surveill.15(12), 19525 (2010).
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI). Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2009–2010. Canada Communicable Disease Report (CCDR)35(ACS-6), 1–41 (2009).
   Google Scholar
• Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years. Clin. Infect. Dis.39(7), 920–927 (2004).
   PubMed Web of Science ®Google Scholar
• Couch RB, Keitel WA, Cate TR. Prevention of influenza virus infections by current inactivated influenza vaccines. In: Options for the Control of Influenza III. Brown LE, Hampson AW, Webster RG (Eds). Elsevier Science, Amsterdam, The Netherlands, 97–106 (1996).
   Google Scholar
• Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med.361(13), 1260–1267 (2009).
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med.355(24), 2513–2522 (2006).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled Phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis.200(2), 172–180 (2009).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med.166(10), 1121–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19(17–19), 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• Herzog C, Hartmann K, Kunzi V et al. Eleven years of Inflexal V – a virosomal adjuvanted influenza vaccine. Vaccine27(33), 4381–4387 (2009).
   PubMed Web of Science ®Google Scholar
• de Bruijn I, Meyer I, Gerez L et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine26(1), 119–127 (2007).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Intanza. EMEA/H/C/000957 (2009).
   Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines7(8), 1201–1204 (2008).
   PubMed Web of Science ®Google Scholar
• Mikszta JA, Laurent PE. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Rev. Vaccines7(9), 1329–1339 (2008).
   PubMed Web of Science ®Google Scholar
• Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann. Allergy39(2), 110–112 (1977).
   PubMedGoogle Scholar
• Francis T Jr, Magill TP. The antibody response of human subjects vaccinated with the virus of human influenza. J. Exp. Med.65, 251–259 (1937).
   PubMedGoogle Scholar
• Brown H, Kasel JA, Freeman DM et al. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J. Infect. Dis.136(Suppl.), S466–S471 (1977).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med.351(22), 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine25(37–38), 6755–6763 (2007).
   PubMed Web of Science ®Google Scholar
• Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vaccine Immunol.14(4), 375–381 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine25(52), 8833–8842 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine25(34), 6423–6430 (2007).
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med.7, 13 (2009).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine26(51), 6614–6619 (2008).
   PubMed Web of Science ®Google Scholar
• Arnou R, Eavis P, Pardo JR et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: randomized, controlled, Phase III trial. Hum. Vaccin.6(4), 1–9 (2010).
   Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis.198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter Phase III study. Vaccine27(52), 7304–7312 (2009).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis.10, 134 (2010).
   PubMed Web of Science ®Google Scholar
• Morelon E, Noble CP, Daoud S et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine28(42), 6885–6890 (2010).
   PubMed Web of Science ®Google Scholar
• Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees’ Perception of Injection (VAPI©) questionnaire. Health Qual. Life Outcomes7, 21 (2009).
   PubMed Web of Science ®Google Scholar
• Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: patient reported outcomes from Phase 3 clinical trials. Hum. Vaccin.6(4) 336–345 (2010).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol.17(2), 135–140 (2001).
   PubMed Web of Science ®Google Scholar
• De Donato S, Granoff D, Minutello M et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine17(23–24), 3094–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Cate TR, Atmar RL et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin. Diagn. Lab. Immunol.3(5), 507–510 (1996).
   PubMedGoogle Scholar
• Ansaldi F, Bacilieri S, Durando P et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine26(12), 1525–1529 (2008).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Nino D, Cate TR, Couch RB. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J. Infect. Dis.198(7), 1016–1018 (2008).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine26(26), 3197–3208 (2008).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine27(3), 454–459 (2009).
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar MM et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med.16(8), 915–920 (2010).
   PubMed Web of Science ®Google Scholar
• Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect.12(4), 280–286 (2010).
   PubMed Web of Science ®Google Scholar
• Herzog C, Hartmann K, Kunzi V et al. Eleven years of Inflexal V – a virosomal adjuvanted influenza vaccine. Vaccine27(33), 4381–4387 (2009).
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96, 1–18 (1997).
   Google Scholar